Search Results for: stem cells for MS

When biotech Geron punted on its embryonic stem cell (ESC) program despite having an ongoing FDA-approved clinical trial for spinal cord injury and tens of millions in loan funding from CIRM, many in the stem cell field were upset to put it mildly. Geron repaid the CIRM loan with interest. At the time, the general […]

I’m doing a series of posts on straightforward reasons why patients should not get unlicensed stem cell treatments. Part 1 of the series was on the risk of losing medical insurance coverage. Today is part 2, which is focused on a serious failing of many for-profit, point-of-care stem cell clinics selling unlicensed treatments: lack of

One of the big issues related to using induced pluripotent stem (iPS) cells is cost. To make iPS cells from each patient for subsequent stem cell-based treatment would cost a fortune, by some estimates $200,000 or more per patient if done one-by-one. It could easily end up not being covered by insurances companies and Medicare,

Pluristem Therapeutics Inc. is a publicly traded (NASDAQ) biotech Israeli company that is developing stem cell treatments based on the use of expanded placental stem cells called PLX cells. The Pluristem PLX drug is not approved for treating patients at this time in any country, however Pluristem has treated a handful of patients via something

The big scandal about alleged, later mostly recanted transplants of iPS cells (for more on iPS cells see here) into human patients centered on one fellow named Hisashi Moriguchi. For more on the case see here. Clearly Moriguchi is to blame for his lies. The paper Yomiuri is also to blame for splashing the unverified

The odds of Mitt Romney becoming our next President seem to be increasing. If Romney becomes our next president, what will he do about stem cells? He’ll be an active enemy of embryonic stem cell research. He’ll support the crazy personhood movement. Why do I say that? Earlier this year I had a run in

I was fortunate enough to do my postdoctoral studies at the Fred Hutchinson Cancer Research Center (aka “The Hutch”) in Seattle. I was a postdoc for more years than I’d like to admit, but it was a wonderful experience. The Hutch is the kind of place where you can imagine making the impossible become possible

The FDA warning letter that Celltex received in late September (but that just went public yesterday–see my initial reaction here) is a possible game-changer for that company in my opinion. Why? The letter outlined in great detail the FDA’s concerns with how Celltex manufactures its stem cell product ranging from lack of documentation to concerns about aseptic/sterile